{"id":110548,"title":"US investment bank states that hVIVO is reinforced by powerful industry momentum.","publisher":"Share Talk","author":"sharetalk","published":"2023-10-13T09:31:14+00:00","modified":"2023-10-13T09:31:14+00:00","canonical_url":"https://www.share-talk.com/us-investment-bank-states-that-hvivo-is-reinforced-by-powerful-industry-momentum/","markdown_url":"https://www.share-talk.com/us-investment-bank-states-that-hvivo-is-reinforced-by-powerful-industry-momentum.md","json_url":"https://www.share-talk.com/us-investment-bank-states-that-hvivo-is-reinforced-by-powerful-industry-momentum.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Andrew Catchpole","antiviral","breast cancer","Cathal Friel","CHIMagents","clinical respiratory drug","Codagenix","COVID-19","Dengue Fever","Dr Andrew Catchpole","Dr Chris Chiu","Gregory Stoloff","hVIVO","Imperial College London","Imutex Ltd","laboratory","Malaria","Open Orphan","ORPH","Oxford BioTherapeutics","pharmaceutical","quarantine clinic","Rahim Fandi","Share Talk","The Lancet","Vaccine","virology","West Nile Virus","Zika"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/10/US-investment-bank-states-that-hVIVO.jpg?fit=1200%2C800&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Stifel’s Insight on hVIVO PLC**\n\nThe esteemed American investment bank, Stifel, has recently launched an analysis of hVIVO PLC – a leading contract research organisation (CRO) that focuses on human challenge clinical trials (HCTs). Stifel suggests a target share price of 27p, which is a notable 42% jump from hVIVO’s existing price of 19p.\n\nhttps://twitter.com/hVIVO_UK/status/1712347616179368053\n\n**Why the Optimism?**\n\nThe optimistic projection is rooted in hVIVO’s persistent financial strength and its pivotal role in the pharma and biotech domains.\n\n- **Unique Positioning:** hVIVO stands out globally for its expertise in HCTs. These trials involve exposing healthy participants to infectious diseases in a strictly regulated setting. For pharmaceutical and biotech companies, this approach is cost-effective, swift, and strategically beneficial. Stifel’s insights hint at hVIVO being the top choice for enterprises because of its vast expertise in HCTs.\n\n- **Financial Growth:** In 2022 alone, hVIVO boasted a remarkable 30% YoY revenue surge and has a three-year CAGR at 51%. By June 30, 2023, its record contracted order book reached £78 million. This provides a clear view of its potential revenues up to late 2024. The firm’s EBITDA for 2022 stood at £9.1 million, translating to an 18.7% margin. For 2023, Stifel anticipates hVIVO’s revenue to touch £55 million with an EBITDA margin of 19%.\n\n- **Revenue Diversification:** hVIVO’s financial foundation is bolstered by two other entities – FluCamp, their volunteer enlistment platform, and Venn Life Sciences, their internal consultancy service. These arms not only supplement hVIVO’s growth but also position it to capitalize on cross-selling opportunities with HCT contracts.\n\n- **The Market’s Future:** The resurgence of interest in infectious diseases and the increasing appeal for HCTs predict a favourable trajectory for hVIVO. Their consistent performance, their growth in contract acquisitions, and plans for facility expansion underpin this confidence. Stifel’s note encapsulates the sentiment: the renewed focus on infectious diseases, coupled with hVIVO’s consistent performance metrics and expansion plans, makes a compelling investment proposition."}